Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for enablement
Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly) Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly) Reviewed by Dr Rose Hughes on Monday, May 18, 2026 Rating: 5
[Guest Post] What the Inari vs. Corteva case really tells us about enablement of plant inventions [Guest Post] What the Inari vs. Corteva case really tells us about enablement of plant inventions Reviewed by Jocelyn Bosse on Saturday, February 14, 2026 Rating: 5
Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo) Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo) Reviewed by Dr Rose Hughes on Monday, December 08, 2025 Rating: 5
Non-reproducible prior art post-G 1/23: Novelty versus inventive step (T 1044/23) Non-reproducible prior art post-G 1/23: Novelty versus inventive step (T 1044/23) Reviewed by Dr Rose Hughes on Tuesday, November 18, 2025 Rating: 5
Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944) Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944) Reviewed by Dr Rose Hughes on Monday, June 10, 2024 Rating: 5
USPTO call for comments: Impact of AI on patentability USPTO call for comments: Impact of AI on patentability Reviewed by Dr Rose Hughes on Sunday, May 19, 2024 Rating: 5
BGH on enablement: disclosure may be enabling without being novelty destroying BGH on enablement: disclosure may be enabling without being novelty destroying Reviewed by Mark Schweizer on Monday, September 06, 2010 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.